A phase IIb, randomized, multicenter, noncomparative pilot study of the safety and efficacy of three docetaxel-based chemotherapy regimens plus bevacizumab +/- trastuzumab for the adjuvant treatment of patients with node-positive and high-risk node-negative breast cancer.

Trial Profile

A phase IIb, randomized, multicenter, noncomparative pilot study of the safety and efficacy of three docetaxel-based chemotherapy regimens plus bevacizumab +/- trastuzumab for the adjuvant treatment of patients with node-positive and high-risk node-negative breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2013

At a glance

  • Drugs Bevacizumab; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Trastuzumab
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 24 Jan 2012 Actual patient number 121 added as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Actual end date Oct 2011 added as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top